Crossbow Therapeutics, Inc.
2 clinical trials · Sponsor
◉ Watch Crossbow Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma. (NCT07779798) | Crossbow Therapeutics, Inc. | 2026-08-01 |
| A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias (NCT06994676) | Crossbow Therapeutics, Inc. | 2025-07-16 |
Track Crossbow Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.